Objective We reviewed the current literature regarding antiretroviral (ARV)-sparing therapy
strategies to determine whether these novel regimens can be considered appropriate …

Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …

Introduction: For two decades, triple combinations of antiretrovirals have been the standard
treatment for HIV infection. The challenges of such lifelong therapy include long-term side …

A nucleoside reverse transcriptase inhibitor (NRTI) backbone is a recommended component
of standard highly active antiretroviral therapy (sHAART). However, long-term NRTI …

Background: Guidelines for the use of antiretroviral agents for HIV-1 infection recommend
combining at least three agents. The toxicity, cost, and complexity of such regimens warrant …

Background Antiretroviral dual regimens including lamivudine and one boosted PI or
dolutegravir are warranted in order to optimize combination ART (cART), prevent long-term …

Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options
for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study …

Objective: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy
in antiretroviral-naive patients. Design: Phase IIb, single-arm, open-label, multicenter study …

Background: Based on the results of the GARDEL trial, we designed a proof of concept study
to evaluate the antiviral efficacy, safety and tolerability of a dual therapy regimen with …

Objectives Several attempts have been made to test different drug-sparing strategies to
reduce the drug-burden and drug-related toxicities. The objective of this meta-analysis was …